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Although a number of genetic defects are commonly as-
sociated with acute myeloid leukemia (AML), a large per-
centage of AML cases are cytogenetically normal. This sug-
gests a functional screen for transforming genes is required
to identify genetic mutations that are missed by cytoge-
netic analyses. We utilized a retrovirus-based cDNA expres-
sion system to identify transforming genes expressed in
cytogenetically normal AML patients. We identified a new
member of the Ras guanyl nucleotide-releasing protein
(RasGRP) family of Ras guanine nucleotide exchange fac-
tors, designating it RasGRP4. Subsequently, cDNA se-
quences encoding rodent and human RasGRP4 proteins
were deposited in GenBankTM. RasGRP4 contains the same
protein domain structure as other members of the RasGRP
family, including a Ras exchange motif, a CDC25 homology
domain, a C1/diacyglycerol-binding domain, and putative
calcium-binding EF hands. We show that expression of Ras-
GRP4 induces anchorage-independent growth of Rat1 fi-
broblasts. RasGRP4 is a Ras-specific activator and, inter-
estingly, is highly expressed in peripheral blood leukocytes
and myeloid cell lines. Unlike other RasGRP proteins, Ras-
GRP4 is not expressed in the brain or in lymphoid cells. We
demonstrated that 32D myeloid cells expressing RasGRP4
have elevated levels of activated Ras compared with con-
trol cells, and phorbol 12-myristate 13-acetate (PMA) treat-
ment greatly enhanced Ras activation. PMA induced mem-
brane localization of RasGRP4 and 32D cells expressing
RasGRP4 were capable of cytokine-independent prolifera-
tion in the presence of PMA. We conclude that RasGRP4 is
a member of the RasGRP family of Ras guanine nucleotide
exchange factors that may play a role in myeloid cell sig-
naling growth regulation pathways that are responsive to
diacylglycerol levels.
Acute myeloid leukemia (AML)1 is a disease of the hemato-
poietic cell system in which there is an aberrant accumulation
of myeloid cells in the peripheral blood and bone marrow (1).
Chromosomal translocations are common in AML, and the
study of these chromosomal abnormalities has led to the iden-
tification of a number of AML-associated oncogenes including
AML1-Eto, PML-RAR, and CBF-MYH11 among others (2).
However, up to 50% of AML cases are cytogenetically normal,
suggesting that subtle genetic defects, including point muta-
tions and small deletions, play a causative role in the develop-
ment of the disease (3). This suggests that a functional screen
of cytogenetically normal AML samples may be an effective
approach to identify these mutations.
Most oncogene screening efforts in the past have utilized cell
lines as sources of expressed genes and inefficient transfection
techniques to deliver these genes to target cells. We have ap-
plied a retrovirus-based cDNA expression system that has been
used to efficiently screen cDNA libraries representing genes
expressed in rodent and human tumor cell lines (4). We ex-
panded this system to utilize primary tumor samples as
sources of expressed oncogenes. This insures that the genes
that are surveyed are those expressed in the cancer patient,
and it also circumvents any mutations or aberrant expression
of genes that may be the result of artificial selection inherent in
the establishment and long-term maintenance of cells in
culture.
We used this highly efficient retroviral-based cDNA expression
system to detect oncogenes in cytogenetically normal AML pa-
tients. Recently, we identified an internal deletion mutation in
the TrkA receptor tyrosine kinase expressed in a patient with
cytogenetically normal AML (5). This mutation would not have
been detected by cytogenetic analyses, demonstrating the cre-
dence of this system to identify oncogenes in these AML patients.
In this study, we describe the isolation of a novel transform-
ing protein expressed in a patient with AML that exhibits
homology to the RasGRP family of Ras activators (6). We have
designated it RasGRP4 and have initiated its characterization
and possible role in myeloid cell oncogenesis. During the course
and review of our studies, R. L. Stevens and colleagues depos-
ited sequences in GenBankTM that encode for the same protein,
which they also designated RasGRP4.2
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EXPERIMENTAL PROCEDURES
Northern Blot Analysis—A human multiple tissue mRNA Northern
blot (BD Biosciences/CLONTECH) was probed per the manufacturer’s
instructions with the open reading frame of RasGRP4 radiolabeled by
random priming.
DNA Plasmids—Wild-type RasGRP4 was cloned by PCR from re-
verse-transcribed total RNA of human peripheral blood leukocytes us-
ing primers designed from sequence information from the AML-derived
RasGRP4 cDNA. This sequence has been assigned the GenBankTM
accession number AF448437. RasGRP4 cDNA and the AML-derived
RasGRP4 cDNA were cloned into pBabepuro-HA, a retroviral vector
designed to place a HA epitope tag coding sequence at the 5-end of the
cDNA, as PCR-amplified EcoRI fragments. These cDNAs were also
cloned into pcDNA3HA, a modified version of pcDNA3 designed to
introduce an HA epitope tag at the 5-end of the cDNA. All plasmid
inserts were confirmed by DNA sequencing. Full-length human Ras-
GRP3 was kindly provided by Takahiro Nagase (Kazusa DNA Research
Institute, Chiba, Japan). The EcoRV/XbaI fragment of RasGRP3 was
subcloned into pcDNA3. RasGRP2 was constructed from two EST
clones (GenBankTM accession numbers aa035643 and t78563) as de-
scribed (7). This construct creates the nonmyristoylated, Rap-specific
form of RasGRP2 (8). A BamHI site was incorporated immediately 5 of
the initiating methionine, and the cDNA was subcloned into the BamHI
and NotI sites of pcDNA3. Rlf was kindly provided by Douglas Andres
(University of Kentucky, Lexington, Kentucky). pFLAG-CMV2-Rap1A
and pFLAG-CMV2-Ha-Ras have been used previously (9).
Library Construction and Screening—A cDNA library of the genes
expressed in the leukocytes of a cytogenetically normal AML patient
was constructed in the pCTV1B vector exactly as we have described
previously (5). The screen for and isolation of transforming genes was
also performed exactly as described previously (5).
Retroviral Production and Cell Culture—Ecotropic retrovirus was
made in 293T cells using the pVPack retroviral production system
(Stratagene). 293T cells and Rat1 fibroblasts were maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum (FBS). 32D (clone 3) mouse myeloid progenitor cells were grown
in RPMI supplemented with 10% FBS and 10% WEHI3B conditioned
medium as a source of IL-3 (10). Stable cell lines were generated by
retroviral infection as previously described (5). Puromycin (Sigma) was
used at a concentration of 1 g/ml to select stable cell lines, and stable
lines were maintained under drug selection. PMA (Calbiochem) was
used at a final concentration of 100 nM in all experiments. 32D cells
expressing H-Ras(61L) have been described previously (5). Soft agar
assays were performed using single-cell suspensions in agar (5  103
Rat1 cells/60-mm dish) as described previously (11).
Measurement of Cellular GTPase Activation—Activation of Ras was
measured utilizing a GST fusion protein containing the Ras-binding
domain (RBD) of Raf-1 as described (12). For experiments with Rat1
cells, 7  105 cells were plated in 100-mm dishes. Twenty-four hours
later the cells were depleted of serum for 18 h and then treated with 100
nM PMA or 0.1% Me2SO for 30 min prior to harvesting. For experiments
with 32D cells, 3  106 cells were plated in 10 ml of growth medium and
grown overnight. Cells were then washed twice with RPMI only and
incubated in 10 ml of RPMI in conical tubes for 1 h before treatment
with 100 nM PMA or 0.1% dimethyl sulfoxide (Me2SO) for 30 min.
Transient activation of GTPases in 293T cells has been described pre-
viously (9).
Subcellular Fractionation—For subcellular fractionation, cells were
cultured and treated the same as for the experiments that measured
cellular GTPase activation (see above). S100/P100 subcellular fraction-
ation was performed essentially as described except the protein in each
fraction was resuspended in 2 sample buffer (20 mM NaPO4 pH 7.0,
20% glycerol, 10% -mercaptoethanol, 0.2 M dithiothreitol, and 0.02%
bromphenol blue) following acetone precipitation (13). Equivalent pro-
portions of S100 and P100 were analyzed by immunoblotting.
32D Cell Growth Analysis—32D cells were washed twice with RPMI
to deplete the culture medium of IL-3 (WEHI3B conditioned medium).
Cells were than plated at a concentration of 2  105/ml in RPMI
supplemented with 10% FBS. 100 nM PMA or 0.1% Me2SO was added,
and cells were counted daily by trypan blue exclusion. Growth medium
with PMA was replenished every 2–3 days.
Immunoblot Analyses—The following antibodies were used for im-
munoblot analyses: anti-HA (Covance), anti-pan Ras (Calbiochem), and
anti-FLAG (Sigma).
RESULTS AND DISCUSSION
Isolation of a Transforming Gene That Encodes a New Ras-
GRP Family Member—To identify transforming genes in cyto-
genetically normal AML, we created and screened cDNA librar-
ies from primary patient samples. We utilized both Rat1
fibroblasts and Rat intestinal epithelial-1 cells as biological
screening assays for genes that induce cellular transformation.
We have determined previously that these lines are useful for
identifying transforming genes because they are efficiently in-
fected by retrovirus and have a very low rate of spontaneous
transformation (5). We independently identified a 2293-bp
cDNA twice as a gene that induces Rat1 cell transformation.
Standard nucleotide BLAST data base searching identified the
cDNA as a previously unidentified gene on human chromosome
19. The cDNA contains an open reading frame that encodes a
673-amino acid protein. An NCBI BLAST search indicated that
the protein encoded by the cDNA is homologous to members of
the Ras guanyl nucleotide-releasing protein (RasGRP) family
of Ras guanine nucleotide exchange factors (6). ClustalW align-
ments indicate that RasGRP4 shows 39% identity to RasGRP2,
38% identity to RasGRP1, and 36% identity to RasGRP3 over
the entire length of the proteins. Therefore, we have designated
this protein RasGRP4. Compared with data base genomic se-
quence as well as two RasGRP4 cDNAs that were isolated by
reverse transcription-polymerase chain reaction (PCR) from
normal individuals, the AML-derived RasGRP4 cDNA contains
a point mutation at codon 620 that changes a glutamic acid to
a lysine in the carboxyl terminus of the protein. The cDNA and
amino acid sequences of wild-type RasGRP4 are shown in
Fig. 1A.
RasGRP4 exhibits a similar domain structure to the three
human members of the RasGRP protein family (Fig. 1B) (6).
There is a central CDC25 homology domain that is known to
exert the catalytic function of guanine nucleotide exchange
factors (GEFs) for Ras family proteins (Ras, R-Ras, Rap, and
Ral proteins). A phylogenetic tree indicating the relationship of
the CDC25 homology domain of RasGRP4 to the CDC25 ho-
mology domains of other human Ras, Rap, or Ral exchange
factors is shown in Fig. 1C. The strongest sequence similarity is
seen with the CDC25 homology domains of RasGRP proteins.
Amino-terminal to the CDC25 homology domain is a Ras ex-
change motif that is present in other Ras exchange factors and
is believed to play a critical role of CDC25 catalytic activity in
vivo but not in vitro.
Carboxyl terminal to the CDC25 homology domain is a C1
domain, a cysteine-rich domain that binds diacylglycerol in
RasGRP and protein kinase C family proteins (14). Diacylglyc-
erol has been shown to regulate RasGRP subcellular location
and catalytic activity (8, 15–17). Finally, other RasGRP family
members contain two calcium-binding EF hands between the
CDC25 homology and C1 domains. This region of RasGRP4,
however, shows only weak homology to these domains. This
weak homology is in part due to a stretch of three prolines in
the second putative EF hand, which may alter its ability to bind
calcium. These prolines are not present in the EF hands of the
other RasGRP proteins. It has been postulated that intracellu-
lar calcium can regulate the activity of RasGRP proteins
through the EF hands (8, 18). However, the effect of calcium on
RasGRP protein activity remains unclear. Finally, unlike Ras-
GRP2, RasGRP4 does not contain a myristylation signal se-
quence at its amino terminus, indicating that RasGRP4 is not
lipid modified in this manner (8).
identical to our isolated transforming sequences, during the course of
our study and the review of our manuscript, R. L. Stevens and col-
leagues also identified mouse (GenBankTM accession numbers
AF331457 and AY040628) and rat (GenBankTM accession numbers
AF465263, AF465264, and NM130824) RasGRP4 cDNAs and submit-
ted an additional human sequence (GenBankTM accession number
XM056604).
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RasGRP4 Tissue Expression Is Distinct from Other RasGRP
Family Members—Previous studies determined that RasGRP1,
RasGRP2, and RasGRP3 show overlapping, but distinct tissue
patterns of gene expression (15, 16, 18–20). Our Northern blot
analysis indicates that RasGRP4 is expressed highly in periph-
eral blood leukocytes (Fig. 1D). Significantly lower transcript
levels are seen in other tissues including heart, skeletal mus-
cle, spleen, liver, placenta, and lung. An 4-kb message is seen
in these tissues. A multiple tissue expression array probed with
the cDNA for RasGRP4 indicated the highest expression of
RasGRP4 in bone marrow and peripheral blood leukocytes and
lower expression in other tissues.3 This expression pattern is
distinct from that described for the other RasGRPs (15, 16,
18–20). In particular, we did not detect RasGRP4 message in
the brain, whereas the other RasGRP transcripts and proteins
3 G. W. Reuther, Q. T. Lambert, and C. J. Der, unpublished
observations.
FIG. 1. Sequence and expression of RasGRP4. A, sequence of wild-type RasGRP4. The nucleotide sequence of wild-type RasGRP4 cDNA is
shown with the corresponding amino acid sequence below it. This sequence has been assigned the GenBankTM accession number AF448437. The
following domains were identified in RasGRP4 using the Simple Modular Architecture Research Tool (smart.embl-heidelberg.de/): a Ras exchange
motif (REM) (amino acids 55–172); a CDC25 homology domain (amino acids 197–433); potential EF hand domains (amino acids 470–498 and
499–528); and a C1 domain (amino acids 541–590). The amino acids of these domains are underlined. B, schematic representation of all RasGRP
family members. C, dendrogram of the CDC25 domains of Ras exchange factors. A dendrogram was derived from a ClustalW alignment of the
CDC25 homology domains of various human Ras, Rap, and Ral guanine nucleotide exchange factors. This was done using the ClustalW program
at the EMBL European Bioinformatics Institute web site (www2.ebi.ac.uk/clustalw/). D, expression of RasGRP4. RasGRP4 cDNA was used as a
probe on a human multiple tissue mRNA Northern blot (BD Biosciences/CLONTECH). The sizes of RNA markers are indicated in kilobases.
Tissues include brain (B), heart (H), skeletal muscle (M), colon (C), thymus (T), spleen (S), kidney (K), liver (Li), small intestine (SI), placenta (P),
lung (Lu), and peripheral blood leukocytes (PBL).
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are expressed highly in this organ (16, 18–20). While RasGRP1
is expressed in lymphoid cells but not myeloid cells (15), high
expression of RasGRP4 in peripheral blood leukocytes and its
isolation from myeloid cells suggests that RasGRP4 may have
a distinct role in these cells. Indeed, Northern analysis using
hematopoietic cell lines indicated that RasGRP4 is highly ex-
pressed in myeloid cells compared with lymphoid cells.3 While
RasGRP1 plays a role in the activation of Ras in response to
T-cell receptor signaling (21, 22), RasGRP4 may function in a
myeloid-specific signaling pathway required for proper devel-
opment and function of cells of this hematopoietic lineage.
To verify that RasGRP4 was the basis for the transformation
seen in our library screen, we established Rat1 fibroblasts stably
infected with a retrovirus expression vector encoding a hemag-
glutinin (HA) epitope-tagged version of RasGRP4. In contrast to
cells infected with the empty vector, the Rat1 cells stably
expressing RasGRP4 cDNA readily grew in soft agar (Fig.
2A). Rat1 cells expressing the AML-derived point-mutated
RasGRP4 promoted equivalent colony formation in soft agar,
indicating that the mutation in the tumor-derived sequence
did not alter the transforming signal of the protein, at least in
the assays that we performed.3 Previous studies have de-
scribed a potent transforming activity for RasGRP1 and a
weak activity for RasGRP3, whereas RasGRP2 did not ex-
hibit transforming activity (19).
RasGRP4 Is a Ras-specific Guanine Nucleotide Exchange
Factor—RasGRPs have been shown to function as GEFs for
Ras and/or Rap proteins (6). Constitutively activated mutants
of Ras, but not Rap1, are potent transforming proteins (23).
Hence, we sought to determine whether RasGRP4 functions as
an activator of Ras. For these analyses, we utilized a glutathi-
one S-transferase (GST) fusion protein containing the GTP-de-
pendent Ras-binding domain from the Ras effector, the Raf-1
serine/threonine kinase, in a pull-down assay (12) to determine
whether the level of activated GTP-bound Ras was elevated in
Rat1 cells stably overexpressing RasGRP4. Cells expressing
the AML-mutated or wild type RasGRP4 contained an elevated
level of GTP-bound Ras when compared with empty vector-
infected control cells (Fig. 2B). As expected from their similar
transforming activities, we found no significant difference in
the ability of the AML-derived point mutated RasGRP4 or
wild-type RasGRP4 to activate Ras. Thus, we conclude that
transformation by RasGRP4 likely occurs by causing persistent
activation of endogenous Ras proteins.
RasGRP2 (in this case the shorter unmyristylated form,
CalDAG-GEFI) activates Rap1 but not Ras (8, 18), whereas
RasGRP3 activates both Ras and Rap (17, 19). Therefore, we
next compared the ability of RasGRP4 to activate Ras and Rap
in 293T cells with that of other RasGRP proteins. These anal-
yses involved pull-down assays using the GST-Raf-RBD for Ras
FIG. 2. RasGRP4 transforms Rat1 fibroblasts and activates Ras in Rat1 fibroblasts and 293T cells. A, RasGRP4 transforms Rat1
fibroblasts. Rat1 cells were generated to express RasGRP4 by retroviral infection. Cells stably expressing RasGRP4 readily formed colonies of
proliferating cells in soft agar (lower panel), whereas control cells expressing the empty vector did not (upper panel). B, RasGRP4 expression
activates Ras in Rat1 fibroblasts. Expression of wild-type RasGRP4 (WT) and the AML-mutated RasGRP4 (A) in Rat1 fibroblasts was detected by
immunoblot analyses of total cell lysates with anti-HA monoclonal antibodies (left panel). The molecular masses of the protein markers are
indicated in kilodaltons. Rat1 fibroblasts stably expressing wild-type RasGRP4, the AML-mutated RasGRP4, or control vector (V) were starved of
serum for 18 h, and the amount of activated GTP-bound Ras was determined utilizing a GST-RafRBD pull-down assay. The amount of bound,
activated Ras-GTP in the pull-downs and total Ras in lysates were visualized by immunoblotting with pan-Ras antibodies (right panels). C,
RasGRP4 activates Ras but not Rap in 293T cells. 293T cells were transfected with expression plasmids (750 ng) encoding empty vector, Rlf,
RasGRP2, RasGRP3, or RasGRP4, together with FLAG epitope-tagged Rap1a or H-Ras (750 ng). After 24 h, cells were starved of serum for 18 h,
and activation of Rap1a and H-Ras was determined by pull-down assays utilizing GST-RalGDSRBD and GST-RafRBD, respectively. The amount
of bound, activated Rap1a-GTP and H-Ras-GTP in the pull-down assays and total transfected Rap1a and H-Ras in lysates were identified by
immunoblotting with anti-FLAG antibodies. D, PMA induces morphological transformation of Rat1 cells expressing RasGRP4. Rat1 fibroblasts
stably expressing RasGRP4 or control vector were treated with dimethyl sulfoxide (DMSO) vehicle or 100 nM PMA, and cell morphology was
photographed under phase contrast microscopy after 48 h.
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and a GST fusion to the RBD of RalGDS to pull down activated
Rap (9, 24) (Fig. 2C). In agreement with previous observations,
we found that RasGRP3 activated both Ras and Rap1, whereas
the Rap-specific short form of RasGRP2 (i.e. CalDAG-GEFI)
activated Rap1 and not Ras. In contrast, transient expression
of RasGRP4 activated Ras but did not activate Rap1 (Fig. 2C).
Expression of Rlf, a guanine nucleotide exchange factor for the
Ral GTPase (25), did not activate Ras or Rap1. Thus, RasGRP4
acts as a Ras-specific GEF and, like other RasGRPs, is not an
activator of Ral.4
PMA Promotes RasGRP4 Membrane Association and GEF
Activity—Diacylglycerol or phorbol ester interaction with the
C1 domain has been shown to promote membrane association
and GEF activity of the three known RasGRP proteins (8,
15–17). To determine whether RasGRP4 function is modulated
by an increase in diacylglycerol, we determined whether treat-
ment with the diacylglycerol analog, PMA, would enhance the
transforming activity of RasGRP4 when expressed in Rat1
cells. PMA treatment induced morphological transformation of
Rat1 cells expressing RasGRP4 but not vector control cells (Fig.
2D), suggesting that PMA further stimulated RasGRP4 activ-
ity. This morphologic transformation is similar to that caused
by expression of constitutively activated mutants of Ras in
Rat1 cells (26, 27). PMA treatment did not significantly in-
crease the ability of Rat1 fibroblasts expressing RasGRP4 to
grow in soft agar.3 However, these cells grew quite efficiently in
soft agar (1500 agar colonies/5000 cells plated) in the absence of
PMA, and thus PMA could only increase soft agar growth by
3-fold at most. Taken together, we interpret these results to
suggest that a lower threshold of Ras activation is sufficient to
promote anchorage-independent growth but not morphologic
transformation. Therefore, although PMA treatment to further
activate Ras did not greatly enhance growth in soft agar, it did
raise the threshold level of Ras to that required for morphologic
transformation.
Previous studies have shown that PMA stimulated RasGRP
function by promoting enhanced plasma membrane association
(8, 15–17). Because RasGRP4 mRNA is expressed highly in
peripheral blood leukocytes and was isolated from a myeloid
leukemia, we evaluated the ability of PMA to regulate Ras-
GRP4 subcellular location and activity in 32D mouse myeloid
progenitor cells (28, 29). For these analyses, we established
32D cells stably expressing HA epitope-tagged RasGRP4 and
then determined whether PMA treatment also promoted mem-
brane association of this exchange factor (Fig. 3A). We treated
32D cells expressing RasGRP4 with PMA for 30 min and per-
formed subcellular fractionation. PMA treatment induced a
translocation of RasGRP4 from the S100 soluble fraction to the
P100 membrane-containing fraction (Fig. 3B). Identical results
were seen in Rat1 cells, with translocation occurring within 5
min of PMA treatment.3
We next determined whether this increase in membrane
association coincided with enhanced Ras activation in 32D cells
expressing RasGRP4. 32D cells expressing RasGRP4 exhibited
elevated basal Ras-GTP levels when compared with control
empty vector-infected cells (Fig 3C). This level of activated Ras
was greatly enhanced by PMA treatment, whereas PMA alone
did not further activate Ras in control cells (Fig. 3C). Rap1 was
not activated under these conditions,3 consistent with the in-
ability of RasGRP4 to activate Rap1 in 293T cells (Fig. 2C). The
elevated basal levels of Ras activation in cells expressing Ras-
GRP4 is likely due to the significant amount of RasGRP4 that
is already associated with membranes (Fig. 3B). Identical re-
sults were obtained with the wild-type and AML-mutated
forms of RasGRP4, suggesting that the AML-derived mutation
does not alter the ability of RasGRP4 to translocate to mem-
branes and activate Ras in response to PMA treatment (Fig. 3,
B and C). These data indicate that RasGRP4, like other Ras-
GRP family members, has a functional C1 diacylglycerol-bind-
ing domain that regulates the activity of the CDC25 domain.
Thus, RasGRP4 likely plays a role downstream of extracellular
stimuli that elicit elevated diacylglycerol levels, such as those
that stimulate G protein-coupled receptor or receptor tyrosine
kinase activation of phospholipase C  or , respectively (30).
RasGRP4 Activation by PMA Promotes Cytokine-independ-
ent Growth of 32D Myeloid Cells—Finally, because had we
identified RasGRP4 as a transforming protein, we determined
whether RasGRP4 was capable of altering the growth proper-
ties of myeloid cells. To evaluate this possibility, we analyzed
the ability of RasGRP4 to promote cytokine-independent
growth of 32D cells. 32D cells require interleukin-3 (IL-3) for
survival and growth (28, 29, 31). Removal of IL-3 from 32D cells4 J. F. Rebhun and L. A. Quilliam, unpublished observations.
FIG. 3. PMA promotes RasGRP4 membrane association and RasGRP4-mediated activation of Ras in 32D myeloid cells. A,
expression of the RasGRP4 proteins in 32D cells was determined by immunoblot analyses of total cell lysates with anti-HA antibodies. The
molecular masses of protein markers are indicated in kilodaltons. V, control vector; A, AML-mutated form; WT, wild type. B, 32D cells stably
expressing wild-type or AML-mutated forms of RasGRP4 were treated with PMA for 30 min and analyzed by S100/P100 fractionation. RasGRP4
present in each fraction was detected by immunoblot analyses with anti-HA antibodies. S, soluble; P, particulate; DMSO, dimethyl sulfoxide. C,
32D cells expressing RasGRP4 proteins were starved of FBS and IL-3 for 1 h and then stimulated with PMA for 30 min, and the relative amount
of activated Ras-GTP was determined by utilizing a GST-RafRBD pull-down assay. The levels of active Ras-GTP in the pull-downs and of total Ras
in lysates were determined by immunoblotting with anti-pan Ras antibodies.
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induces a rapid and complete apoptotic response resulting in
all cells dying within 48 to 72 h. Expression of several leuke-
mia-associated oncogenes (e.g. Bcr-Abl, Flt3) promotes the
growth and survival of these cells in the absence of IL-3 (32,
33). Expression of RasGRP4 in 32D cells did not alter the rate
of cell death in response to IL-3 withdrawal. However, treat-
ment of these cells with PMA resulted in an increase in cell
viability5 and promoted 32D cell growth in the absence of IL-3
(Fig. 4, B and C). This IL-3 independence is reversible, as
removal of PMA from the growth medium resulted in apoptosis
of the culture.5 PMA did not affect the survival or growth of
control cells in the absence of IL-3 (Fig. 4A). Thus, PMA-
mediated activation of RasGRP4 can promote growth transfor-
mation of mouse myeloid cells.
Our observation that activation of RasGRP4 can promote
IL-3-independent growth of 32D cells was unexpected, because
we and others had found that expression of activated versions
of Ras in 32D cells does not induce IL-3-independent growth,
although activated Ras can inhibit apoptosis in these cells (34,
35). PMA treatment of 32D cells expressing constitutively ac-
tivated H-Ras(61L) did not promote IL-3 independence, sug-
gesting that the affect of PMA on RasGRP4 cells is not merely
a cooperation between Ras activation and other signals acti-
vated by PMA (Fig. 4D). Similar results were obtained with
32D cells expressing activated K-Ras(12V) or N-Ras(12D).5
This suggests that aberrant activation of RasGRP4 in myeloid
cells may promote the transformation of myeloid cells to a
growth factor-independent state more efficiently than acti-
vated alleles of Ras itself. How might this occur? One possibil-
ity is that RasGRP4 activation likely causes concurrent activa-
tion of multiple Ras isoforms, and possibly R-Ras family
proteins, hence causing a quantitatively stronger and qualita-
tively distinct activation of signaling pathways from those ac-
tivated by a single mutated Ras protein. Alternatively, it is
possible that RasGRP4 activation of Ras, causing the rapid
GDP/GTP cycling of Ras, has different downstream signaling
consequences than are caused by GTPase-deficient, chronically
GTP-bound activated Ras. Evidence for this latter possibility is
provided from observations that fast GDP/GTP-cycling mu-
tants of Rho small GTPases show greater transforming potency
than GTPase-deficient mutants (36). To test this possibility, we
expressed two different Ras mutants, H-Ras(117E) and
H-Ras(119H), in 32D cells. Although these mutants have an
increased rate of cycling between GDP/GTP binding and are
highly transforming (37), they were unable to transform 32D
cells to IL-3 independence.5 Cells expressing these forms of Ras
behaved similarly to 32D cells expressing GTPase-deficient
H-Ras(61L) in the absence of IL-3 (Fig. 4D). We confirmed the
H-Ras(117E) and H-Ras(119H) DNA constructs used in these
experiments were highly transforming in NIH3T3 cells.3 This
finding suggests that the effect of PMA-activated RasGRP4 on
32D cell growth may be mediated by concurrent activation of
multiple Ras isoforms or other Ras-like GTPases (e.g. R-Ras) by
RasGRP4.
During the course of our studies, Stevens and colleagues2
deposited a human cDNA sequence encoding a protein nearly
identical to RasGRP4 (GenBankTM accession number
AY048119). The sequence of this protein is identical to what we
found for wild-type RasGRP4 except for three amino acid posi-
tions. Amino acid positions 120, 261, and 671 are Gln, Arg, and
Leu, respectively, in our sequence, and Leu, Cys, and Pro,
respectively, in their sequence. The reason for these discrepan-
cies is unclear, but the sequences at these positions were iden-
tical in the three different cDNA sources we utilized. Identified5 G. W. Reuther and C. J. Der, unpublished observations.
FIG. 4. PMA promotes RasGRP4-mediated cytokine-independent growth of 32D myeloid cells. 32D cells expressing control vector (A),
wild-type RasGRP4 (B), AML-derived RasGRP4 (C), or H-Ras(61L) (D) were deprived of IL-3 on day zero and cultured in the presence (closed
symbols) or absence (open symbols) of 100 nM PMA. The total number of viable cells was determined by trypan blue exclusion.
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as a mast cell-restricted signaling protein in an asthma pa-
tient, the Stevens’ group2 also designated their protein Ras-
GRP4, and they further identified human sequences that en-
coded defective variants of RasGRP4 (GenBankTM accession
numbers AY048120, AY048121, and NM052949). Whether
these defective variants are simply inactive proteins or func-
tion as dominant negative proteins that can block the function
of other RasGRP proteins, will be interesting to determine. In
addition, after the submission of our study, the Stevens’ group2
also identified mouse (GenBankTM accession numbers
AF331457 and AY040628) and rat (GenBankTM accession num-
bers AF465263, AF465264, and NM130824) RasGRP4 cDNAs
and submitted an additional human sequence (GenBankTM
accession numbers XM056604).
In summary, we have identified a new member (RasGRP4) of
the RasGRP family of Ras family guanine nucleotide exchange
factors through a screen for transforming genes expressed in
AML patients. Although the patient-derived cDNA encodes for
a mutated protein, our analyses did not determine a functional
difference from wild-type RasGRP4. Perhaps the mutated form
will exhibit altered functions in other biological assays or,
alternatively, simply represents a polymorphism. Is the aber-
rant activation of RasGRP4 important for AML development?
The chromosomal location of RasGRP3 is involved in chromo-
somal rearrangements in AML, and proviral integration-medi-
ated activation of RasGRP2 has been observed in a mouse
model of AML (17, 20). Interestingly, sequence analysis using
the NCBI Genome data base indicates RasGRP4 is located at
chromosome 19q13, a region identified as undergoing rear-
rangement in human leukemias and other cancers (38). Thus,
aberrant regulation of RasGRP4 may be a common undiscov-
ered event in AML development. Is Ras activation important
for AML oncogenesis? N-Ras is frequently mutated in AML
patients (39, 40), although it has been proposed that at least
two oncogenic events are required to induce AML (41). Also,
activation of the ERK (extracellular signal-regulated kinase)
pathway, a major downstream component of Ras signaling, is
seen in about half of all AML cases (42). This suggests that
direct (e.g. point mutation of N-Ras) or indirect (possibly
through RasGRP4 activation) stimulation of Ras signaling
plays an important role in AML. Our future studies will eval-
uate whether RasGRP4 is aberrantly overexpressed or acti-
vated in human AML and whether Ras-mediated signaling
pathways are important for AML development.
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